Dongsheng Tu
机构: Professor of Biostatistics, Queen's University at Kingston, Canada
每年引用次数
引用次数
引用: 50,542
H-指数: 84
I10-指数 : 235
出版物: 544
Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15).
Andrea Bezjak , Peter Dixon , Michael Brundage , Dong Sheng Tu
International Journal of Radiation Oncology Biology Physics 54 ( 3) 719 -728
126
2002
Two one-sided tests procedures in establishing therapeutic equivalence with binary clinical endpoints: fixed sample performances and sample size derformination
Tu Dongsheng
Journal of Statistical Computation and Simulation 59 ( 3) 271 -290
6
1997
Duration projection for equivalence clinical trials with survival endpoints
Tu Dongsheng , Benny Zee , Joseph Pater
Controlled Clinical Trials 19 ( 3)
1998
Asymptotic expansion of random weighting method
Tu Dongsheng , Zheng Zongguo
The Chinese Journal of Applied Probability and Statistics 3 ( 4) 340 -347
3
1987
Tissue and plasma tumor mutation burden (TMB) as predictive biomarkers in the CO. 26 trial of durvalumab plus tremelimumab (D plus T) versus best supportive care (BSC) in metastatic colorectal cancer (mCRC).
Jonathan M Loree , James T Topham , Hagen F Kennecke , Harriet Feilotter
JOURNAL OF CLINICAL ONCOLOGY 39 ( 3)
2021
The jackknife and bootstrap
Jun Shao , Dongsheng Tu
3,218
1995
Comment on: A placebo-controlled randomized clinical trial of perioperative administration of gabapentin, rofecoxib and their combination for spontaneous and movement-evoked pain after abdominal hysterectomy by Gilron I, et al., Authors' reply
Ian Gilron , Henrik Kehlet , Dongsheng Tu , Jorgen B. Dahl
Pain 115 218 -219
2005
Bayesian inference for treatment-biomarker interaction in clinical trials
Bingshu. E. Chen , Dongsheng Tu , W. Jiang
2016
Predicting outcome after initial relapse of epithelial ovarian cancer: can we identify patients who will not benefit from further therapy?
Martine van Glabbeke , Jan B. Vermorken , Keith James , Dongsheng Tu
CME journal of gynecologic oncology 4 ( 1) 64 -68
3
1999
Tissue and plasma tumor mutation burden (TMB) as predictive biomarkers in the CO.26 trial of durvalumab + tremelimumab (D+T) versus best supportive care (BSC) in metastatic colorectal cancer (mCRC).
Harriet Feilotter , Derek J. Jonker , Kimberly Banks , Christopher J. O'Callaghan
Journal of Clinical Oncology 39 61 -61
2021
ctDNA-based mutational landscape following anti-EGFR antibodies in metastatic colorectal cancer (mCRC) to uncover novel resistance mechanisms in the CCTG CO.26 trial.
Harriet Feilotter , Derek Jonker , Kimberly Banks , Christopher J. O'Callaghan
Journal of Clinical Oncology 39 117 -117
2021
Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs. GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
Mustapha Tehfe , Derek J. Jonker , Patricia A. Tang , Petr Kavan
Journal of Clinical Oncology 39 411 -411
6
2021
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial
Rongyu Zang , Yanling Feng , Dongsheng Tu , Sheng Yin
Lancet Oncology 22 ( 4) 439 -449
91
2021
Estimation of the binomial probabilities in a two-stage phase II clinical trial with two co-primary endpoints
Xianming Tan , Dongsheng Tu , Yiming Sun , Xinyi Zhang
Contemporary Clinical Trials 105 106390 -106390
2021
Factors predicting missing instruments in three cancer randomized clinical trials.
Michael J. Palmer , Harriet Richardson , Dongsheng Tu , Michael Brundage
Quality of Life Research 1 -16
2021
Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R.
Josee-Lyne Ethier , Geoffrey M Anderson , Peter C Austin , Mark Clemons
European Journal of Cancer 149 117 -127
2021
Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC).
Di Maria Jiang , Hao-Wen Sim , Lillian L Siu , Jeremy David Shapiro
Journal of Clinical Oncology 35 699 -699
2017
Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years.
Julie Lemieux , Michael D. Brundage , Wendy R. Parulekar , Paul E. Goss
Journal of Clinical Oncology 36 ( 6) 563 -571
11
2018
A phase I study of a PD-L1 antibody (Durvalumab) in combination with trastuzumab in HER-2 positive metastatic breast cancer (MBC) progressing on prior anti HER-2 therapies (CCTG IND.229)[NCT02649686].
Stephen KL Chia , Philippe L Bedard , John Hilton , Eitan Amir
Journal of Clinical Oncology 36 1029 -1029
13
2018
A Randomized Phase II study of Reolysin in Patients with Previously Treated Advanced or Metatstatic Non Small Cell Lung Cancer (NSCLC) receiving Standard Salvage Chemotherapy – Canadian Cancer Trials Group IND 211.
Donald Morris , Dongsheng Tu , Mustapha Ali Tehfe , Garth Andrew Nicholas
Journal of Clinical Oncology 34
3
2016
Lois Shepherd Lesley Seymour Kathleen I. Pritchard C Karapetis John Zalcberg Jeremy Shapiro Timothy Price Christopher J O'Callaghan Michael Brundage Wendy R. Parulekar Ian Gilron John Goffin Lillian Siu Ronald R. Holden Nancy E Davidson Penelope Bradbury Stephen KL Chia Zee Chung-Ying Benny Ming Tsao Sharlene Gill